News

Filter

1 to 9 of 36 results

Highlights from the Jefferies 2014 Global Healthcare Conference

Highlights from the Jefferies 2014 Global Healthcare Conference

21-11-2014

Pharma, biotech and health care companies convened in London this week to update investors at the Jefferies…

ALK AbelloClinigen GroupCubistFinancialGW PharmaceuticalsPeter GeorgePharmaceuticalUK

GW Pharmaceuticals granted orphan designation by the EMA for Epidiolex

GW Pharmaceuticals granted orphan designation by the EMA for Epidiolex

22-10-2014

Cannabinoid product specialist GW Pharmaceuticals has been granted orphan designation by the European…

CNS DiseasesepidiolexGW PharmaceuticalsPharmaceuticalResearchUSA

GW shares rise on positive Epidiolex efficacy data

GW shares rise on positive Epidiolex efficacy data

18-06-2014

UK-based GW Pharmaceuticals has announced physician reports of efficacy and safety data from its investigational…

epidiolexGW PharmaceuticalsNeurologicalPharmaceuticalResearchUK

US FDA grants Fast Track designation for GW Pharma’s Epidiolex in Dravet syndrome

US FDA grants Fast Track designation for GW Pharma’s Epidiolex in Dravet syndrome

06-06-2014

The US Food and Drug Administration has granted Fast Track designation to UK-based GW Pharmaceuticals’…

epidiolexGW PharmaceuticalsPharmaceuticalRare diseasesRegulationTreatment of Dravet syndromeUSA

GW Pharma and New York State to initiate trials of cannabidiol in epilepsy

GW Pharma and New York State to initiate trials of cannabidiol in epilepsy

04-06-2014

UK-based GW Pharmaceuticals, a biopharmaceutical company focused on developing novel therapeutics from…

epidiolexGW PharmaceuticalsMedication-resistant epilepsyNeurologicalPharmaceuticalResearchUSA

GW Pharma shows drop in revenue but expects ‘steady progress’

GW Pharma shows drop in revenue but expects ‘steady progress’

07-05-2014

UK-based GW Pharmaceuticals, a biopharmaceutical company focused on developing novel therapeutics from…

FinancialGW PharmaceuticalsNeurologicalPharmaceuticalSativexUK

GW Pharmaceuticals appoints Kenneth Sommerville as VP, Clinical Science

GW Pharmaceuticals appoints Kenneth Sommerville as VP, Clinical Science

07-05-2014

UK-based GW Pharmaceuticals has announced the appointment of Kenneth Sommerville to the newly created…

BoardroomGW PharmaceuticalsPharmaceuticalUKUSA

US FDA grants Sativex fast track status for cancer pain

US FDA grants Sativex fast track status for cancer pain

28-04-2014

UK-based GW Pharmaceuticals, which focuses on its proprietary cannabinoid product platform, today announced…

Advanced cancerAnalgesiaCancerGW PharmaceuticalsOncologyOptimized chronic opioid therapyPainPharmaceuticalRegulationSativexTreatment of pain in patients with advanced cancerUK

1 to 9 of 36 results

Back to top